Vivos Therapeutics (VVOS) Capital Expenditures Growth (1y) (2021 - 2026)
Vivos Therapeutics (VVOS) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.66 Bn | 175.36 Bn | 6.27 Bn | -17.56% |
| 2 | Stryker | 128.55 Bn | 125.68 Bn | 3.81 Bn | 34.96% |
| 3 | Medtronic | 108.38 Bn | 99.16 Bn | 6.41 Bn | 6.32% |
| 4 | Boston Scientific | 68.11 Bn | 66.66 Bn | 3.61 Bn | -5.35% |
| 5 | Edwards Lifesciences | 47.19 Bn | 43.52 Bn | 1.29 Bn | 15.89% |
| 6 | Dexcom | 28.54 Bn | 27.42 Bn | 750.30 Mn | -11.95% |
| 7 | GE HealthCare Technologies | 28.37 Bn | 26.09 Bn | 1.98 Bn | 106.98% |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.53 Bn | 22.40 Bn | 2.07 Bn | -47.73% |
| 10 | Vivos Therapeutics | 5.77 Mn | 3.66 Mn | 3.06 Mn | -85.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.25% |
| Dec 31, 2025 | 2,551.52% |
| Sep 30, 2025 | -143.23% |
| Jun 30, 2025 | 1,185.00% |
| Mar 31, 2025 | -19.21% |
| Dec 31, 2024 | -78.09% |
| Sep 30, 2024 | 144.24% |
| Jun 30, 2024 | -86.18% |
| Mar 31, 2024 | 202.00% |
| Dec 31, 2023 | 276.50% |
| Sep 30, 2023 | -534.00% |
| Jun 30, 2023 | -13.89% |
| Mar 31, 2023 | -58.33% |
| Dec 31, 2022 | -47.64% |
| Sep 30, 2022 | -77.32% |
| Jun 30, 2022 | -61.56% |
| Mar 31, 2022 | -54.20% |
| Dec 31, 2021 | 302.15% |
| Sep 30, 2021 | 3,573.78% |
| Jun 30, 2021 | 16,701.23% |